Advancing drug innovation for neglected diseases - Criteria for lead progression

PLoS Neglected Tropical Diseases

Volumn 3, Issue 8, 2009, Pages

  Nwaka, Solomon ^a   Ramirez, Bernadette ^a   Brun, Reto ^b   Maes, Louis ^c   Douglas, Frank ^d   Ridley, Robert ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d EWING MARION KAUFFMAN FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BENZNIDAZOLE; CHLOROQUINE; EFLORNITHINE; IVERMECTIN; MILTEFOSINE; PRAZIQUANTEL; STIB 795; TDR 15949; TDR 17516; TDR 20364; TDR 22093; TDR 42098; TDR 44218; TDR 44219; UNCLASSIFIED DRUG;

AFRICAN TRYPANOSOMIASIS; ANTIMALARIAL ACTIVITY; DEVELOPING COUNTRY; DRUG DESIGN; DRUG INDUSTRY; DRUG METABOLISM; DRUG RESEARCH; DRUG SCREENING; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; HEALTH CARE ORGANIZATION; HEALTH CARE SYSTEM; HIGH THROUGHPUT SCREENING; HUMAN; MALARIA; MEDICAL TECHNOLOGY; NONHUMAN; ONCHOCERCIASIS; PLASMODIUM FALCIPARUM; REVIEW; SCHISTOSOMIASIS; SOCIOECONOMICS; STRUCTURE ACTIVITY RELATION; TROPICAL DISEASE; VISCERAL LEISHMANIASIS;

EID: 70449640250     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000440     Document Type: Review

References (63)

1. Nwaka S, Hudson A (2006) Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov 5: 941-955. (Pubitemid 44660607)
2. World Health Organization (2006) Public health, innovation and intellectual property rights. Report of the Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH). Geneva: WHO.
3. Nwaka S, Ridley RG (2003) Virtual drug discovery and development for neglected diseases through public-private partnerships. Nat Rev Drug Disc 2: 919-928. (Pubitemid 37419900)
4. DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22: 151-185.
5. Adams CP, Brantner VV (2006) Estimating the cost of new drug development: Is it really 802 million dollars? Health Aff (Millwood) 25: 420-428.
6. World Health Organization (2004) The world health report 2004: changing history. Geneva: WHO.
7. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, et al. (2002) Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 359: 2188-2195. (Pubitemid 34694030)
8. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI (2005) The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434: 214-217. (Pubitemid 40388051)
9. Greenwood BM, Fidock DA, Kyle DE, Kappe SH, Alonso PL, et al. (2008) Malaria: progress, perils and prospects for eradication. J Clin Invest 118: 1266-1276.
10. Breman JG, Alilio MS, Mills Al (2004) Conquering the intolerable burden of malaria: what's new, what's needed: a summary. Am J Trop Med Hyg 71: 1-15.
11. Noedl H, SeYoury, Schaecher K, Smith B, Socheat D, et al. (2008) Evidence of atemisinin-resistant malaria in Western Cambodia. N Engl J Med 359: 2619-2620.
12. Casenghi M, Cole ST, Nathan CF (2007) New approaches to filling the gap in tuberculosis drug discovery. PLoS Med 4: e293. doi:10.1371/journal. pmed.0040293.
13. Teixeira AR, Nitz N, Guimaro MC, Gomes C, Santos-Buch CA (2006) Chagas disease. Postgrad Med J 82: 788-798.
14. Duschak V, Couto AS (2007) An insight on targets and patented drugs for chemotherapy of Chagas disease. Recent Patents Anti Infect Drug Discov 2: 19-51. (Pubitemid 46729086)
15. LePape P (2008) Development of new antileishmanial drugs - current knowledge and future prospects. J Enzyme Inhib Med Chem 1: 1.
16. Ramirez B, Bickle Q, Yousif F, Fakorede F, Mouries MA, et al. (2007) Schistosomes: challenges in compound screening. Exp Opin Drug Discov 2: S53-S61.
17. Townson S, Ramirez B, Fakorede F, Mouries MA, Nwaka SN (2007) Challenges in drug discovery for novel antifilarials. Exp Opin Drug Discov 2: S63-S73. (Pubitemid 47616031)
18. Boatin B, Richards FO (2006) Control of onchocerciasis. Adv Parasitol 61: 349-394.
19. Prichard R (2007) Ivermectin resistance and overview of the Consortium for Anthelminthic Resistance SNPs. Exp Opin Drug Discov 2: S41-S52. (Pubitemid 47616029)
20. Prichard RK, von Samson-Himmelstjerna G, Blackhall WJ, Geary TG (2007) Towards markers for anthelminthic resistance in helminths of importance in animal and human health. Parasitology 134: 1073-1076.
21. Nwaka S, Widdus R (2004) The research to development transition for candidate products to combat neglected diseases. In: Widdus R, White K, eds. Combating diseases associated with poverty: financing strategies for product development and the potential role of public-private partnerships. Initiative on Public-Private Partnerships for Health. Geneva: Global Forum for Health Research. pp 164-168.
22. Moran M (2005) A breakthrough in R&D for neglected diseases: new ways to get the drugs we need. PLoS Med 2: e302. doi:10.1371/journal.pmed.0020302.
23. McKerrow JH (2005) Designing drugs for parasitic diseases of the developing world. PLoS Med 2: e210. doi:10.1371/journal.pmed.0020210.
24. Bill & Melinda Gates Foundation (2008) Grand Challenges in Global Health initiative. Available: http://www.gatesfoundation.org/global-health/ Pages/ grand-challenges-explorations.aspx. Accessed 30 July 2009.
25. TheWellcome Trust (2008) Research capacity strengthening in Africa [press release]. Available: http://www.wellcome.ac.uk/News/Media-office/Press- releases/2008/ WTD039430.htm. Accessed 30 July 2009.
26. BIO Ventures for Global Health (2007) Closing the global health innovation gap. A role for the biotechnology industry in drug discovery for neglected diseases. Available: http://www.bvgh.org/documents/InnovationMap.pdf. Accessed 30 July 2009.
27. Hopkins A, Witty MJ, Nwaka S (2007) Mission possible. Nature 449: 166-169.
28. Janssens PG, Kivits M, Vuylsteke J (1992) Medecine et hygiene en Afrique Centrale de 1885 a nos jours. Brussels: Fondation Roi Baudouin.
29. Croft SL (2005) Public-private partnership: from there to here. Trans Roy Soc Trop Med Hyg 99: S9-S14.
30. Horton J (2003) Drug development for tropical diseases - present situation, future perspectives. Trends Parasitol 19: P06.
31. Gutteridge WE (2006) TDR collaboration with the pharmaceutical industry. Trans Roy Soc Trop Med Hyg 100: S21-S25.
32. Special Programme for Research and Training in TropicalDiseases (2007)Making a difference: 30 years of research and capacity building in tropical diseases. Geneva: WHO/TDR, Available: http://www.who.int/tdr/svc/ publications/ tdrnews/issue-81/making-difference. Accessed 30 July 2009.
33. Croft SL, Engel J (2006) Miltefosine-discovery of the antileishmanial activity of phospholipid derivatives. Trans R Soc Trop Med Hyg 100: S4-S8. (Pubitemid 44490168)
34. Ashburn T, Thor K (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3: 673-683. (Pubitemid 39173508)
35. Nwaka S (2005) Drug discovery and beyond: the role of public-private partnerships in improving access to new malaria medicines. Trans Royal Soc Trop Med Hyg 99: S20-S29.
36. Pink R, Hudson A, Mouries MA, Bendig M (2005) Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Disc 4: 727-740. (Pubitemid 43090494)
37. Vennerstrom JL (2004) Identification of an antimalarial synthethic trioxolane drug development candidate. Nature 430: 838-839.
38. TDR (2008) Lead discovery for drugs for infectious tropical diseases. Available: http://www.who.int/tdr/svc/research/lead-discovery-drugs. Accessed 30 July 2009.
39. Hudson A, Nwaka S (2007) The concept paper on the Helminth Drug Initiative. Onchocerciasis/lymphatic filariasis and schistosomiasis: opportunities and challenges for the discovery of new drugs/diagnostics. Exp Opin Drug Discov 2: S3-S7.
40. WHO/TDR and Japanese Parasitology Society (2007) Summary report from the Helminth Drug Initiative Consultation Meetings: informal consultation of experts to advice TDR on the proposed initiative. Exp Opin Drug Discov 2: S99-S103.
41. Masum H, Daar AS, Al-Bader S, ShahRonak, Singer PA (2007) Accelerating Health Product Innovation in sub-Saharan Africa. MIT Press J 2: 129-149.
42. Perrin D, Scheer A, Wells T (2006) Collaborating to find new approaches to tropical diseases. Eur Pharma Rev 3: 52-55.
43. WHO/TDR (2008) African Network for Drugs and Diagnostics Innovation. Creating a sustainable platform for R&D innovation in Africa. Proceedings of the inaugural meeting, 6-8 October 2008; Abuja, Nigeria. Part 1: Health product R&D landscape in Africa. Part 2: Collection of meeting abstracts. Geneva: WHO/TDR. Available: http://www.who.int/tdr/news-events/news/ pdf/ANDI-rd-landscape-abstracts.pdf. Accessed 30 July 2009.
44. Bajorath J (2002) Integration of virtual and high-throughput screening. Nat Rev Drug Disc 1: 882-893.
45. Blundell TL, Jhoti H, Abell C (2002) High-throughput crystallography for lead discovery in drug design. Nat Rev Drug Disc 1: 45-54. (Pubitemid 37361403)
46. Bleicher KH, Bohm HJ, Muller K, Alanine AI (2003) Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Disc 2: 369-378. (Pubitemid 37361707)
47. Baldwin J, Michnoff CH, Malmquist NA, White J, Roth MG, et al. (2005) High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J Biol Chem 280: 21847-21853. (Pubitemid 40827835)
48. Gribbon P, Sewing A (2005) High throughput drug discovery: what can we expect from HTS? Drug Discov Today 10: 17-22.
49. Hopkins AL, Groom CR (2003) Target analysis: a priori assessment of druggability. Ernst Schering Res Found Workshop 42: 11-17.
50. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6: 29-40.
51. Holloway GA, Baell JB, Fairlam AH, Novello PM, Parisot JP, et al. (2007) Discovery of 2-iminobenzimidazoles as a new class of trypanothione reductase inhibitor by high-throughput screening. Bioorg Med Chem Lett 17: 1422-1427.
52. Gardner MJ, Hall N, Fung E, White O, Berriman M, et al. (2002) Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419: 498-511.
53. Ivens AC, Peacock CS, Worthey EA, Murphy L, Aggarwal G, et al. (2005) The genome of the kinetoplastid parasite, Leishmania major. Science 309: 436-442.
54. Berriman M, Ghedin E, Hertz-Fowler C, Blandin G, Renauld H, et al. (2005) The genome of the African trypanosome Trypanosoma brucei. Science 309: 416-422. (Pubitemid 40994676)
55. El-Sayed NM, Myler PJ, Bartholomeu DC, Nilsson D, Aggarwal G, et al. (2005) The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 309: 409-415. (Pubitemid 40994675)
56. Haas BJ, Berriman M, Hirai H, Cerqueira GG Loverde PT, et al. (2007) Schistosoma mansoni genome: closing in on a final gene set. Exp Parasitol 117: 225-228. (Pubitemid 350001186)
57. Ghedin E, WangShilian, Spiro D, Caler E, Zhao Q, et al. (2007) Draft genome of the filarial nematode parasite Brugia malayi. Science 317: 1756-1760. (Pubitemid 47461841)
58. WHO/TDR (2008) WHO/TDR targets database. Available: http://www. tdrtargets. org and http://apps.who.int/tdr/svc/news-events/news/open-access- database. Accessed 30 July 2009.
59. Aguero F, Al-Lazikani B, Aslett M, Berriman M, Buckner FS, et al. (2008) Genomic-scale prioritization of drug targets: the TDR Targets database. Nat Rev Drug Discov 7: 900-907.
60. WHO/TDR (2008) New drug screening programme set up in China [press release]. Available: http://apps.who.int/tdr/svc/news-events/news/chinese-drug- screening. Accessed 30 July 2009.
61. Lipinski C (2000) Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44: 235-249.
62. World Health Organization (2008) Global strategy and plan of action on public health innovation and intellectual property. Sixty-first World Health Assembly, agenda item 11.6. Available: http://www.who.int/gb/ebwha/pdf-files/ A61/ A61-R21-en.pdf. Accessed 30 July 2009.
63. Morel C, Acharya T, Broun D, Dangi A, Elias C, et al. (2005) Health innovation networks to help developing countries address neglected diseases. Science 309: 401-404. (Pubitemid 40994673)